Aminologics Co.Ltd (074430) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aminologics Co.Ltd (074430) has a cash flow conversion efficiency ratio of 0.081x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.62 Billion ≈ $3.13 Million USD) by net assets (₩57.11 Billion ≈ $38.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Aminologics Co.Ltd's balance sheet to measure how much of total assets are equity-financed.
Aminologics Co.Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Aminologics Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Aminologics Co.Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Aminologics Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aminologics Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rayence Co. Ltd
KQ:228850
|
0.022x |
|
U&I Corporation
KQ:056090
|
-0.034x |
|
Mirae Asset Daewoo Co Ltd
KO:006805
|
-0.323x |
|
Skane mollan AB
ST:SKMO
|
0.022x |
|
Akin Tekstil AS
IS:ATEKS
|
0.001x |
|
Evertex Fabrinology Ltd
TW:1470
|
0.041x |
|
CENIT Aktiengesellschaft
XETRA:CSH
|
0.303x |
|
Cintac
SN:CINTAC
|
0.119x |
Annual Cash Flow Conversion Efficiency for Aminologics Co.Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of Aminologics Co.Ltd from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see 074430 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩55.99 Billion ≈ $37.95 Million |
₩2.54 Billion ≈ $1.72 Million |
0.045x | -68.58% |
| 2024-12-31 | ₩51.70 Billion ≈ $35.03 Million |
₩7.47 Billion ≈ $5.06 Million |
0.144x | +3702.19% |
| 2023-12-31 | ₩54.41 Billion ≈ $36.87 Million |
₩-218.15 Million ≈ $-147.84K |
-0.004x | -103.94% |
| 2022-12-31 | ₩51.40 Billion ≈ $34.84 Million |
₩5.23 Billion ≈ $3.54 Million |
0.102x | +545.46% |
| 2021-12-31 | ₩59.39 Billion ≈ $40.25 Million |
₩935.52 Million ≈ $633.99K |
0.016x | -52.29% |
| 2020-12-31 | ₩53.56 Billion ≈ $36.30 Million |
₩1.77 Billion ≈ $1.20 Million |
0.033x | -52.50% |
| 2019-12-31 | ₩51.85 Billion ≈ $35.14 Million |
₩3.60 Billion ≈ $2.44 Million |
0.070x | -18.90% |
| 2018-12-31 | ₩53.19 Billion ≈ $36.04 Million |
₩4.56 Billion ≈ $3.09 Million |
0.086x | +28.94% |
| 2017-12-31 | ₩45.14 Billion ≈ $30.59 Million |
₩3.00 Billion ≈ $2.03 Million |
0.066x | -28.45% |
| 2016-12-31 | ₩44.55 Billion ≈ $30.19 Million |
₩4.14 Billion ≈ $2.80 Million |
0.093x | +132.53% |
| 2015-12-31 | ₩48.28 Billion ≈ $32.72 Million |
₩1.93 Billion ≈ $1.31 Million |
0.040x | +161.59% |
| 2014-12-31 | ₩31.85 Billion ≈ $21.58 Million |
₩-2.07 Billion ≈ $-1.40 Million |
-0.065x | -127.90% |
| 2008-12-31 | ₩52.44 Billion ≈ $35.54 Million |
₩12.19 Billion ≈ $8.26 Million |
0.233x | -- |
About Aminologics Co.Ltd
Aminologics Co.,Ltd., a specialty amino acid provider, develops a range of amino-acid-based raw materials for pharmaceutical and fine chemical industries in South Korea. Its products include D-phenylalanine, D-alanine, D-cysteine, D-serine, D-allo-isoleucine, D-allo-threonine, S-beta-phenylalanine, 3-(2-napthyl)-D-alanine, 4-chloro-D-phenylalanine, 3-(2-napthyl)-L-alanine, R-beta-phenylalanine, D… Read more